Učitavanje...
TopBP1 contributes to the chemoresistance in non-small cell lung cancer through upregulation of p53
Resistance to chemotherapeutic drugs is a major obstacle in non-small cell lung cancer (NSCLC) therapy. The molecular determinants of NSCLC resistance to doxorubicin are unknown. In the present study, we investigated whether topoisomerase IIβ binding protein 1 (TopBP1) was involved in the chemoresis...
Spremljeno u:
| Izdano u: | Drug Des Devel Ther |
|---|---|
| Glavni autori: | , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Dove Medical Press
2016
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5042189/ https://ncbi.nlm.nih.gov/pubmed/27729767 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S90705 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|